Hybrid imaging PET/MR in prostatic carcinoma
Authors:
Jiří Ferda; Eva Ferdová; Radek Tupý; Jan Baxa
Authors‘ workplace:
Klinika zobrazovacích metod LF UK a FN Plzeň
Published in:
Čas. Lék. čes. 2018; 157: 169-174
Category:
Review Article
Overview
Imaging of the own prostatic tissue is being not easy using standard tumour imaging approaches, contrast enhanced computed tomography and the hybrid imaging using PET/CT with the application of the 18F-fluorodeoxyglucose. Magnetic resonance imaging is useful in detection of the patients with the elevated prostatic specific antigen (PSA) and/or with the increased index of the health prostate index (PHI).
The novel imaging possibilities of the imaging is hybrid positron emission tomography – magnetic resonance imaging (PET/MR) with the application of 18F-fluorocholine (FCH), 18F-natriumfluoride (18F-NaF) or 68Ga-PSMA-11 (ligand of prostatic specific membrane antigen) in detection, staging or restaging of the prostatic carcinoma. PET/MR represents current optimal method of the staging, restaging and therapy response evaluation of prostatic carcinoma.>
Keywords:
prostatic carcinoma, PET/MR, 18F-fluorocholine, 18F-natriumfluoride, 68Ga-PSMA-11
Sources
1. Eineluoto JT, Järvinen P, Kenttämies A et al. Repeat multiparametric MRI in prostate cancer patients on active surveillance. PLoS One 2017; 12(12): e0189272.
2. Brembilla G, Dell'Oglio P, Stabile A et al. Preoperative multiparametric MRI of the prostate for the prediction of lymph node metastases in prostate cancer patients treated with extended pelvic lymph node dissection. Eur Radiol 2018; 28(5): 1969–1976.
3. Kozlowski P, Chang SD, Jones EC, Goldenberg SL. Assessment of the need for DCE MRI in the detection of dominant lesions in the whole gland: Correlation between histology and MRI of prostate cancer. NMR Biomed 2018; 31(3).
4. Gaunay G, Patel V, Shah P et al. Role of multi-parametric MRI, of the prostate for screening and staging: Experience with over 1500 cases. Asian J Urol 2017; 4(1): 68–74.
5. Druskin SC, Tosoian JJ, Young A et al. Incorporating prostate health index density, mri, and prior negative biopsy status to improve the detection of clinically significant prostate cancer. BJU Int 2018; 121(4): 619–626.
6. Mischinger J, Kaufmann S, Russo GI et al. Targeted versus systematic robot-assisted transperineal MRI-TRUS fusion prostate biopsy. BJU Int 2018; 121(5): 791–798.
7. Schmid DT, John H, Zweifel R et al. Fluorocholine PET/CT in patients with prostate cancer: initial experience. Radiology 2005; 235(2): 623–628.
8. Cimitan M, Bortolus R, Morassut S et al. [18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging 2006; 33(12): 1387–1398.
9. Kwee SA, Coel MN, Lim J. Detection of recurrent prostate cancer with 18F-fluorocholine PET/CT in relation to PSA level at the time of imaging. Ann Nucl Med 2012; 26(6): 501–507.
10. Graute V, Jansen N, Ubleis C et al. Relationship between PSA kinetics and [18F]fluorocholine PET/CT detection rates of recurrence in patients with prostate cancer after total prostatectomy. Eur J Nucl Med Mol Imaging 2012; 39(2): 271–282.
11. Kjölhede H, Ahlgren G, Almquist H et al. Combined 18F-fluorocholine and 18F-fluoride positron emission tomography/computed tomography imaging for staging of high-risk prostate cancer. BJU Int 2012; 110(10): 1501–1506.
12. Umbehr MH, Müntener M, Hany T et al. The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis. Eur Urol 2013; 64(1): 106–117
13. Dundee PE, Hutton AC, Eden CG. [18F]fluorocholine positron-emission/computed tomography for lymph node staging of patients with prostate cancer: preliminary results of a prospective study. BJU Int 2011; 107(1): 158–159
14. Afshar-Oromieh A, Zechmann CM, Malcher A et al. Comparison of PET imaging with a 68Ga-labeled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2014; 41(1): 11–20.
15. Beer AJ, Eiber M, Souvatzoglou M et al. Radionuclide and hybrid imaging of recurrent prostate cancer. Lancet Oncol 2011; 12(2): 181–191.
16. Castellucci P, Picchio M. 11C-choline PET/CT and PSA kinetics. Eur J Nucl Med Mol Imaging 2013; 40(Suppl. 1): 36–40
Labels
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain managementArticle was published in
Journal of Czech Physicians
Most read in this issue
- Hybrid imaging PET/MR in prostatic carcinoma
- Coronary CT angiography – current options and future perspectives in the diagnosis of coronary artery disease
- Contrast-enhanced ultrasonography
- Interventional radiology therapies for liver cancer